Gilead Sciences, Inc. $GILD Shares Purchased by Matrix Trust Co

Matrix Trust Co increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,295 shares of the biopharmaceutical company’s stock after purchasing an additional 107 shares during the quarter. Matrix Trust Co’s holdings in Gilead Sciences were worth $144,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of GILD. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth $25,000. Activest Wealth Management lifted its holdings in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences in the first quarter valued at $29,000. Colonial Trust Advisors lifted its holdings in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares during the period. Finally, Core Alternative Capital lifted its holdings in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 241 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.4%

GILD opened at $114.09 on Monday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock has a market capitalization of $141.56 billion, a price-to-earnings ratio of 22.73, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36. The business has a 50-day moving average of $114.10 and a two-hundred day moving average of $109.98. Gilead Sciences, Inc. has a 12 month low of $81.83 and a 12 month high of $121.83.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences’s payout ratio is 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the sale, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. The trade was a 1.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at $18,120,661.35. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,390,030 in the last 90 days. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of recent analyst reports. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. Royal Bank Of Canada raised their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a report on Friday, August 8th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. UBS Group raised their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Finally, JPMorgan Chase & Co. raised their target price on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $117.17.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.